CardieX

CardieX

Vascular biomarker technology for cardiovascular health management.

HQ location
Itasca, United States
Launch date
Employees
Market cap
$10.2m
Enterprise value
$11m
Share price
AUD0.03
Recent deals
  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
*
N/A

AUD4.1m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
AUD2018201920202021202220232024
Revenues0000000000000000000000000000
% growth-25 %-20 %(17 %)20 %107 %
EBITDA0000000000000000000000000000
% EBITDA margin(75 %)(60 %)(60 %)(83 %)(240 %)(250 %)(58 %)
Profit0000000000000000000000000000
% profit margin(75 %)(60 %)(60 %)(100 %)(240 %)(317 %)(62 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article

Notes (0)
More about CardieX
Made with AI
Edit

CardieX is a global health technology company, listed on the Australian Stock Exchange, that designs, manufactures, and markets solutions for cardiovascular health disorders. The company was founded in 1994 and is headquartered in Sydney, Australia. Its core business revolves around its patented and FDA-cleared SphygmoCor® technology, which is considered a market leader for non-invasively measuring central blood pressure and arterial stiffness. This technology provides deeper insights into cardiovascular health than traditional blood pressure measurements by assessing the pressure that the heart, brain, and kidneys directly experience.

The company operates through two main divisions: ATCOR and CONNEQT. The ATCOR division focuses on the clinical market, supplying medical devices to specialist clinicians, pharmaceutical companies for clinical trials, and research institutions. Its technology is used by 8 of the top 10 pharmaceutical companies and in all of the top 20 U.S. hospitals. The CONNEQT division, launched in 2021, targets the consumer and home healthcare market. Its product line includes the CONNEQT Pulse, a dual blood pressure monitor for home use, and the upcoming CONNEQT Band, a health wearable. These devices integrate the SphygmoCor technology into an ecosystem of connected apps and digital solutions for consumers, remote patient monitoring, and decentralized clinical trials.

The company's business model is transitioning towards recurring revenue streams. This includes sales and leasing of devices, technology licensing, and a move towards subscription-based services for both its clinical (XCEL) and consumer (Pulse) platforms, which offer features like on-demand cardiology reports. CardieX is led by Group CEO Craig Cooper, a serial entrepreneur who co-founded Boost Mobile (USA) and has an extensive background in venture capital, digital media, and technology.

Keywords: cardiovascular diagnostics, arterial stiffness, central blood pressure, vascular biomarker technology, SphygmoCor, remote patient monitoring, wearable health devices, hypertension management, digital health solutions, non-invasive diagnostics, ATCOR, CONNEQT Pulse, clinical trials, medical devices, home health monitoring, telehealth, vital signs monitoring, cardiovascular disease, FDA-cleared, biometric monitor

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by CardieX

Edit
Blumio
ACQUISITION by CardieX Nov 2022